SCOPE

Fact Sheet

# Respiratory

SCOPE is an **independent, global CRO** with proven expertise in r**espiratory indications** across clinical **phases I–IV**. Our experience spans paediatric trials, orphan drugs, medical devices, non-interventional, and post-authorization studies. Close collaborations with leading investigators and KOLs worldwide allow us to **deliver high-quality**, tailored solutions for your development programmes.

## Proven Experience that Delivers

Our expertise ensures reliable study planning, engaged sites, effective recruitment, and minimised trial risks – saving time and protecting your investment.

**37** / **Completed Respiratory Studies**

**1,300** / **Qualified Sites**

**24,000** / **Subjects**

## Global Reach & Experience

Since 2000, SCOPE has conducted over 300 studies with 88,000 subjects, including 37 recent respiratory trials. With 11 offices across Europe and a global partner net-work, we operate wherever clinical trial services are required.

**Highlights:**

- Phase I–IV respiratory trials, from single protocols to full development programmes
- Extensive experience across multiple respiratory disease states

# Your CRO of Choice for _____ Respiratory

## Why Respiratory Trials Need SCOPE

With the rising incidence of respiratory diseases and allergies, specialized trial expertise is essential. SCOPE consistently meets enrolment targets on time and on budget, supporting custom recruitment strategies.

## Key Advantages

- **Efficient patient recruitment & site engagement**
- **Tailored approaches for each clinical stage**
- **Rapid feasibility assessments & consulting**
- **Large international investigator networks**
- **more ...**

## Trial Capabilities & Study Design

We manage a wide range of study types, including Phase I–III trials, post-authorization studies, adaptive designs, and complex device/diagnostic combination studies.

**Expertise includes:**

- Device trials for Asthma, COPD, ARDS, Hypercapnic Respiratory Failure, RSV in children
- Biostatistical support for randomization, stratification, non-inferiority, adaptive designs
- Post-marketing & pharmacoeconomic assessments

## What Sets SCOPE Apart

Our team of experienced project managers, CRAs, data managers, biostatisticians, and medical staff are fully versed in respiratory protocols. Strong investigator and KOL relationships enable rapid feasibility, consulting, and decision-making.

**Differentiators:**

- Dedicated respiratory/pulmonology expertise
- Low employee turnover, ensuring consistency and continuity
- Proven track record in achieving enrolment and regulatory objectives
- Tailored strategies for patient recruitment, site management, and trial execution

## Therapeutic Areas

- Asthma (mild, moderate, severe, paediatrics)
- COPD
- COVID-19
- Asthma/COPD-Overlapping Syndrome (ACOS)
- Development of a dry-powder inhaler
- CAP (Community-Acquired Pneumonia)

PROVEN RESULTS IN RESPIRATORY

★ ★ ★ ★ ★

### “Reliable delivery in complex respiratory trials”

SCOPE combined strong respiratory expertise with pragmatic study management. Recruitment targets were met despite complex protocols and demanding timelines.

Clinical Development Lead, Pharmaceutical Company

**SCOPE International AG**
Konrad-Zuse-Ring 18
68163 Mannheim, Germany
Phone +49 621 42939 0

For further information please contact
SCOPE’s Business Development Team:
**contact@scope-international.com**

www.scope-international.com

Follow us on in